Paul Kelly - Dec 17, 2021 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
Director
Signature
/s/ Paul Kelly
Stock symbol
RLMD
Transactions as of
Dec 17, 2021
Transactions value $
$0
Form type
4
Date filed
5/26/2022, 06:43 PM
Next filing
Jan 5, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLMD Stock Option (right to buy) Award $0 +182K +155.25% $0.00 300K May 25, 2022 Common Stock 182K $19.03 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders.
F2 The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022.